谷胱甘肽S-转移酶μ3对乳腺癌细胞株MDA-MB-231生物学特性的影响
|
摘要
目的:
研究谷胱甘肽S-转移酶μ3(glutathione S-transferase mu 3,GSTM3)在乳腺癌中的作用,建立GSTM3稳定过表达或沉默的乳腺癌细胞株MDA-MB-231,初步观察GSTM3对乳腺癌细胞株MDA-MB-231生物学特性的影响。
方法:
构建GSTM3真核表达重组质粒pcDNA3.1/GSTM3,并利用真核表达载体pSilencer 2.1-U6 neo构建GSTM3特异性siRNA表达质粒;以脂质体转染法将构建好的正确重组质粒和对照载体质粒分别转染MDA-MB-231细胞,RT-PCR和荧光定量PCR法检测GSTM3 mRNA水平,western blot筛选GSTM3蛋白表达改变的稳定细胞株;应用MTT法和细胞划痕运动实验,观察GSTM3对MDA-MB-231细胞体外增殖能力、迁移运动及蒽环类抗肿瘤药物阿霉素敏感性等影响。
结果:
1.转染GSTM3真核表达质粒,经RT-PCR、荧光实时定量PCR和western实验证明,GSTM3过表达的稳定乳腺癌细胞株MDA-MB-231成功建立。
2.转染GSTM3特异性siRNA表达质粒,并经RT-PCR和荧光实时定量PCR实验证明,GSTM3表达沉默的稳定乳腺癌细胞株MDA-MB-231成功建立。
3.GSTM3对MDA-MB-231细胞生物学特性的影响:①GSTM3过表达和沉默后对MDA-MB-231细胞体外增殖能力均无明显影响(P＞0.05);②划痕运动试验中,GSTM3表达沉默的MDA-MB-231细胞划痕愈合快(P＜0.05),GSTM3过表达的MDA-MB-231细胞则愈合慢(P＜0.05);③GSTM3过表达后,MDA-MB-231细胞对蒽环类抗肿瘤药物阿霉素的敏感性增加(P＜0.05),GSTM3表达沉默后,MDA-MB-231细胞对阿霉素敏感性降低(P＜0.05)。
结论:
1.成功构建GSTM3过表达和沉默的乳腺癌细胞株MDA-MB-231。
2.GSTM3表达改变对乳腺癌细胞MDA-MB-231体外增殖能力无明显影响,主要改变细胞对阿霉素的药物敏感性,并影响细胞的迁移运动能力,从而改变乳腺癌细胞转移的倾向。
Objective:
For further study on the role of GSTM3 in breast cancer, MDA-MB-231 breast cancer cell lines in which GSTM3 is overexpressed or silenced were constructed. The effects of overexpressing or silencing of GSTM3 on MDA-MB-231 cells were investigated.
Methods:
PCR was done to amplify the cDNA sequences of GSTM3 from prepared cDNA. The product was subcloned into pcDNA3.1 mammalian expression vector to obtain recombinant pcDNA3.1/GSTM3. The oligonucleotide sequences encoding the GSTM3 -specific siRNA were designed and subcloned into the vector pSilencer2.1-U6 neo, designated pSilencer-272, pSilencer-363 and pSilencer-529. These recombinant plasmids were transfected into MDA-MB-231 cells respectively. Expression level of GSTM3 mRNA and protein were analyzed by RT-PCR, real-time quantitative PCR and western blot. Using cell proliferation, cell migration assay, then the effect of GSTM3 on MDA-MB-231 cells proliferation and motility were investigated in vitro. Growth inhibition of ADM on cells was measured by the MTT assay.
Results:
1. Analyzed by semi-quantitative RT-PCR, real-time RT-PCR and Western blot, overexpression of GSTM3 was detected in cells transfected with pcDNA3.1/GSTM3.
2. Analyzed by semi-quantitative RT-PCR and real-time RT-PCR, GSTM3 expression was significantly decreased in the siRNA interfered cell lines.
3. The effects of GSTM3 overexpression or silenced on the breast cancer cell line MDA-MB-231:①GSTM3 overexpression or silencing did not alter proliferation of MDA-MB-231 cells in vitro.②MDA-MB-231 cells motility was inhibited significantly by GSTM3 overexpression, and accelerated by GSTM3 silencing.③Overexpression of GSTM3 increased inhibitory effect of ADM on MDA-MB-231 cells, but the effect was reversed by GSTM3 silencing.
Conclusion:
1. MDA-MB-231 cell lines in which GSTM3 are stably overexpressed or silenced has been obtained.
2. GSTM3 overexpression inhibited MDA-MB-231 cells motility, and enhanced inhibitory effect of ADM on MDA-MB-231 cells. And GSTM3 silencing promoted cells motility, and decreased inhibitory effect of ADM on MDA-MB-231 cells. The results indicated that GSTM3 might be associated with invasiveness and chemosensitivity of breast cancer cells.
研究谷胱甘肽S-转移酶μ3(glutathione S-transferase mu 3,GSTM3)在乳腺癌中的作用,建立GSTM3稳定过表达或沉默的乳腺癌细胞株MDA-MB-231,初步观察GSTM3对乳腺癌细胞株MDA-MB-231生物学特性的影响。
方法:
构建GSTM3真核表达重组质粒pcDNA3.1/GSTM3,并利用真核表达载体pSilencer 2.1-U6 neo构建GSTM3特异性siRNA表达质粒;以脂质体转染法将构建好的正确重组质粒和对照载体质粒分别转染MDA-MB-231细胞,RT-PCR和荧光定量PCR法检测GSTM3 mRNA水平,western blot筛选GSTM3蛋白表达改变的稳定细胞株;应用MTT法和细胞划痕运动实验,观察GSTM3对MDA-MB-231细胞体外增殖能力、迁移运动及蒽环类抗肿瘤药物阿霉素敏感性等影响。
结果:
1.转染GSTM3真核表达质粒,经RT-PCR、荧光实时定量PCR和western实验证明,GSTM3过表达的稳定乳腺癌细胞株MDA-MB-231成功建立。
2.转染GSTM3特异性siRNA表达质粒,并经RT-PCR和荧光实时定量PCR实验证明,GSTM3表达沉默的稳定乳腺癌细胞株MDA-MB-231成功建立。
3.GSTM3对MDA-MB-231细胞生物学特性的影响:①GSTM3过表达和沉默后对MDA-MB-231细胞体外增殖能力均无明显影响(P＞0.05);②划痕运动试验中,GSTM3表达沉默的MDA-MB-231细胞划痕愈合快(P＜0.05),GSTM3过表达的MDA-MB-231细胞则愈合慢(P＜0.05);③GSTM3过表达后,MDA-MB-231细胞对蒽环类抗肿瘤药物阿霉素的敏感性增加(P＜0.05),GSTM3表达沉默后,MDA-MB-231细胞对阿霉素敏感性降低(P＜0.05)。
结论:
1.成功构建GSTM3过表达和沉默的乳腺癌细胞株MDA-MB-231。
2.GSTM3表达改变对乳腺癌细胞MDA-MB-231体外增殖能力无明显影响,主要改变细胞对阿霉素的药物敏感性,并影响细胞的迁移运动能力,从而改变乳腺癌细胞转移的倾向。
Objective:
For further study on the role of GSTM3 in breast cancer, MDA-MB-231 breast cancer cell lines in which GSTM3 is overexpressed or silenced were constructed. The effects of overexpressing or silencing of GSTM3 on MDA-MB-231 cells were investigated.
Methods:
PCR was done to amplify the cDNA sequences of GSTM3 from prepared cDNA. The product was subcloned into pcDNA3.1 mammalian expression vector to obtain recombinant pcDNA3.1/GSTM3. The oligonucleotide sequences encoding the GSTM3 -specific siRNA were designed and subcloned into the vector pSilencer2.1-U6 neo, designated pSilencer-272, pSilencer-363 and pSilencer-529. These recombinant plasmids were transfected into MDA-MB-231 cells respectively. Expression level of GSTM3 mRNA and protein were analyzed by RT-PCR, real-time quantitative PCR and western blot. Using cell proliferation, cell migration assay, then the effect of GSTM3 on MDA-MB-231 cells proliferation and motility were investigated in vitro. Growth inhibition of ADM on cells was measured by the MTT assay.
Results:
1. Analyzed by semi-quantitative RT-PCR, real-time RT-PCR and Western blot, overexpression of GSTM3 was detected in cells transfected with pcDNA3.1/GSTM3.
2. Analyzed by semi-quantitative RT-PCR and real-time RT-PCR, GSTM3 expression was significantly decreased in the siRNA interfered cell lines.
3. The effects of GSTM3 overexpression or silenced on the breast cancer cell line MDA-MB-231:①GSTM3 overexpression or silencing did not alter proliferation of MDA-MB-231 cells in vitro.②MDA-MB-231 cells motility was inhibited significantly by GSTM3 overexpression, and accelerated by GSTM3 silencing.③Overexpression of GSTM3 increased inhibitory effect of ADM on MDA-MB-231 cells, but the effect was reversed by GSTM3 silencing.
Conclusion:
1. MDA-MB-231 cell lines in which GSTM3 are stably overexpressed or silenced has been obtained.
2. GSTM3 overexpression inhibited MDA-MB-231 cells motility, and enhanced inhibitory effect of ADM on MDA-MB-231 cells. And GSTM3 silencing promoted cells motility, and decreased inhibitory effect of ADM on MDA-MB-231 cells. The results indicated that GSTM3 might be associated with invasiveness and chemosensitivity of breast cancer cells.
引文
[1]Li LF,Xu XJ,Zhao Y,et al.Integrated gene expression profile predicts prognosis of breast cancer patients.Breast Cancer Res Treat,2009,113(2):231-237.
[2]Paik S,Shak S,Tang G,et al.A multigene assay to predict recurrence of tamoxifen-treated,node-negative breast cancer.N Engl J Med,2004,351(27):2817-2826.
[3]Wang Y,Klijn JG,Zhang Y,et al.Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.Lancet,2005,365(9460):671-679.
[4]van 't Veer LJ,Dai H,van de Vijver MJ,et al.Gene expression profiling predicts clinical outcome of breast cancer.Nature,2002,415(6871):530-536.
[5]Goldhirsch A,Wood WC,Gelber RD,et al.Meeting highlights:Updated international expert consensus on the primary therapy of early breast cancer.J Clin Oncol,2003,21(17):3357-3365.
[6]Marty M,Cognetti F,Maraninchi D,et al.Randomized phase ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:The m77001study group.J Clin Oncol,2005,23(19):4265-4274.
[7]Parl FF.Glutathione s-transferase genotypes and cancer rise Cancer Lett,2005,221(2):123-129.
[8]Mcllwain CC,Townsend DM,Tew KD.Glutathione s-transferase polymorphisms:Cancer incidence and therapy.Oncogene,2006,25(11):1639-1648.
[9]Lee SH,DeJong J.Microsomal gst-i:Genomic organization,expression,and alternative splicing of the human gene.Biochim Biophys Acta,1999,1446(3):389-396.
[10]Inskip A,Elexperu-Camiruaga J,Buxton N,et al.Identification of polymorphism at the glutathione s-transferase,gstm3 locus:Evidence for linkage with gstml*a.Biochem J,1995,312(Pt3)(713-716.
[11]Yengi L,Inskip A,Gilford J,et al.Polymorphism at the glutathione s-transferase locus gstm3:Interactions with cytochrome p450 and glutathione s-transferase genotypes as risk factors for multiple cutaneous basal cell carcinoma.Cancer Res,1996,56(9):1974-1977.
[12]Liu X,Campbell MR,Pittman GS,et al.Expression-based discovery of variation in the human glutathione s-transferase m3 promoter and ftmctional analysis in a glioma cell line using allele-specific chromatin immunoprecipitation.Cancer Res,2005,65(1):99-104.
[13]Mitrunen K,Jourenkova N,Kataja V,et al.Glutathione s-transferase ml,m3,pl,and tl genetic polymorphisms and susceptibility to breast cancer.Cancer Epidemiol Biomarkers Prey, 2001,10(3):229-236.
[14]Koutros S,Bemdt SI,Sinha R,et al.Xenobiotic metabolizing gene variants,dietary heterocyclic amine intake,and risk of prostate cancer.Cancer Res,2009,69(5):1877-1884.
[15]Gemignani F,Landi S,Szeszenia-Dahrowska N,et al.Development of lung cancer before the age of 50:The role of xenobiotic metabolizing genes.Carcinogenesis,2007,28(6):1287-1293.
[16]Jain M,Kumar S,Lal P,et al.Role of gstm3 polymorphism in the risk of developing esophageal cancer.Cancer Epidemiol Biomarkers Prey,2007,16(1):178-181.
[17]Livak KJ,Schmittgen TD.Analysis of relative gene expression data using real-time quantitative per and the 2(-delta delta c(t)) method.Methods,2001,25(4):402-408.
[18]Schleicher E,Wieland OH.Evaluation of the bradford method for protein determination in body fluids.J Clin Chem Clin Biochem,1978,16(9):533-534.
[19]Lo HW,Ali-Osman F.Genetic polymorphism and function of glutathione s-transferases in tumor drug resistance.Curr Opin Pharmacol,2007,7(4):367-374.
[20]Ruwali M,Pant MC,Shah PP,et al.Polymorphism in cytochrome p450 2a6 and glutathione s-transferase pl modifies head and neck cancer risk and treatment outcome.Mutat Res,2009:
[21]Lourenco GJ,Neri IA,Sforni VC,et al.Polymorphisms of glutathione s-trausferase mu 1,glutathione s-transferase theta 1 and glutathione s-transferase pi 1 genes in hodgkin's lymphoma susceptibility and progression.Leuk Lymphoma,2009:1-5.
[22]Piipari R,Nurminen T,Savela K,et al.Glutathione s-transferases and aromatic DNA adducts in smokers' bronchoalveolar macrophages.Lung Cancer,2003,39(3):265-272.
[23]Singh H,Sachan R,Devi S,et al.Association of gstml,gsttl,and gstm3 gene polymorphisms and susceptibility to cervical cancer in a north indian population.Am J Obstet Gynecol,2008,1980):303 e301-306.
[24]Holley SL,Rajagopal R,Hoban PR,et al.Polymorphisms in the glutathione s-trausferase mu cluster are associated with turnout progression and patient outcome in colorectal cancer.Int J Oncol,2006,28(1):231-236.
[25]Dirr H,Reinemer P,Huber R.X-ray crystal structures of cytosolie glutathione s-transferases.Implications for protein architecture,substrate recognition and catalytic function.Eur J Biochem,1994,220(3):645-661.
[26]张飚,李永清,高轩.谷胱甘肽 s-转移酶综述.吉林畜牧兽医,2006,27(006):11-13.
[27]刘军,汪永红,王昌富.谷胱甘肽 s-转移酶-π 的生物学特性及其临床应用.INTERNATIONAL JOURNAL,2007,28(1):57-58.
[28]Wang W,Liu G,Zheng J.Human renal uokl30 tumor cells:A drug resistant cell line with highly selective over-expression of glutathione s-transferase-pi isozyme.Eur J Pharmacol,2007,568(1-3):61-67.
[29]Zhou C,Nitsehke AM,Xiong W,et al.Proteomie analysis of tumor necrosis factor-alpha resistant human breast cancer celia reveals a mek5/erk5-mediated epithelial-mesenchymal transition phenotype.Breast Cancer Res,2008,10(6):R105.
[30]O'Brien M,Kruh GD,Tew KD.The influence of coordinate overexpression of glutathione phase ⅱ detoxification gene products on drug resistance.J Pharmacol Exp Ther,2000,294(2):480-487.
[31]郑肖利,陈建明.阳性脂质体介导基因转染及其研究进展.中国新药杂志,2007,16(023):1930-1935.
[32]Fire A,Xu S,Montgomery MK,et al.Potent and specific genetic interference by double-stranded ma in caenorhabditis elegans.Nature,1998,391(6669):806-811.
[33]Minotti G,Menna P,Salvatorelli E,et al.Anthracyclines:Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.Pharmacol Rev,2004,56(2):185-229.
[34]Huang G,Mills L,Worth LL.Expression of human glutathione s-transferase pl mediates the chemosensitivity of osteosarcoma cells.Mol Cancer Ther,2007,6(5):1610-1619.
[35]Cho SG,Lee YH,Park HS,et al.Glutathione s-transferase mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1.J Biol Chem,2001,276(16):12749-12755.
[36]Adler V,Yin Z,Fuchs SY,et al.Regulation of jnk signaling by gstp.EMBO J,1999,18(5):1321-1334.
[37]Townsend DM,Tew KD.The role of glutathione-s-transferase in anti-cancer drug resistance.Oncogene,2003,22(47):7369-7375.
[38]Lu M,Xia L,Luo D,et al.Dual effects of glutathione-s-transferase pi on as2o3 action in prostate cancer cells:Enhancement of growth inhibition and inhibition of apoptosis.Oncogene,2004,23(22):3945-3952.
[39]Yin Z,Ivanov VN,Habelhah H,et al.Glutathione s-transferase p elicits protection against h2o2-induced cell death via coordinated regulation of stress kinases.Cancer Res,2000,60(15):4053-4057.
[1]Parl FF.Glutathione s-transferase genotypes and cancer risk[J].Cancer Lett,2005,221(2):123-129.
[2]McIlwain CC,Townsend DM,Tew KD.Glutathione s-transferase polymorphisms:Cancer incidence and therapy[J].Oncogene,2006,25(11):1639-1648.
[3]Frova C.Glutathione transferases in the genomics era:New insights and perspectives[J].Biomol Eng,2006,23(4):149-169.
[4]Comstoek KE,Widersten M,Hao XY,et al.A comparison of the enzymatic and physieochemical properties of human glutathione transferase m4-4 and three other human mu class enzymes[J].Arch Biochem Biophys,1994,311(2):487-495.
[5]Campbell E,Takahashi Y,Abramovitz M,et al.A distinct human testis and brain mu-class glutathione s-transferase.Molecular cloning and characterization of a form present even in individuals lacking hepatic type mu isoenzymes[J].J Biol Chem,1990,265(16):9188-9193.
[6]Mitrunen K,Hirvonen A.Molecular epidemiology of sporadic breast cancer.The role of polymorphie genes involved in oestrogen biosynthesis and metabolism[J].Mutat Res,2003,544(1):9-41.
[7]Bieche I,Girault I,Urbain E,et al.Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma[J].Breast Cancer Res,2004,6(3):R252-263.
[8]Mitrunen K,Jourenkova N,Kataja V,et al.Glutathione s-transferase ml,m3,pl,and tl genetic polymorphisms and susceptibility to breast cancer[J].Cancer Epidemiol Biomarkers Prey,2001,10(3):229-236.
[9]Li LF,Xu XJ,Zhao Y,et al.Integrated gene expression profile predicts prognosis of breast cancer patients[J].Breast Cancer Res Treat,2008:
[10]van 't Veer LJ,Dai H,van de Vijver MJ,et al.Gene expression profiling predicts clinical outcome of breast cancer[J].Nature,2002,415(6871):530-536.
[11]Watson MB,Lind MJ,Smith L,et al.Expression microarray analysis reveals genes associated with in vitro resistance to cisplatin in a cell line model[J].Acta Oncol,2007,46(5):651-658.
[12]Monge M,Vilaseca M,Soto-Cerrato V,et al.Proteomic analysis ofprodigiosin-indueed apoptosis in a breast cancer mitoxantrone-resistant(mcf-7 mr) cell line[J].Invest New Drugs,2007,25(1):21-29.
[13]Zienolddiny S,Campa D,Lind H,et al.A comprehensive analysis of phase ⅰ and phase ⅱ metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers[J].Carcinogenesis,2008,29(6):1164-1169.
[14]Piipari R,Nurminen T,Savela K,et al.Glutathione s-transferases and aromatic DNA adducts in smokers' bronchoalveolar macrophages[J].Lung Cancer,2003,390):265-272.
[15]Ye Z,Song H,Higgins JP,et al.Five glutathione s-transferase gene variants in 23,452 cases of lung cancer and 30,397 controls:Meta-analysis of 130 studies[J].PLoS Med,2006,3(4):e91.
[16]Gemignani F,Landi S,Szeszenia-Dabrowska N,et al.Development of lung cancer before the age of 50:The role ofxenobiotie metabolizing genes[J].Carcinogenesis,2007,28(6):1287-1293.
[17]De Roos AJ,Rothman N,Brown M,et al.Variation in genes relevant to aromatic hydrocarbon metabolism and the risk of adult brain tumors[J].Neuro Oncol,2006,8(2):145-155.
[18]Singh H,Sachan R,Devi S,et al.Association of gstml,gsttl,and gstm3 gene polymorphisms and susceptibility to cervical cancer in a north indian population[J].Am J Obstet Gynecol,2008,198(3):303 e301-306.
[19]Schwartzbaum JA,Ahlbom A,Loun S,et al.An international case-control study of glutathione transferase and functionally related polymorphisms and risk of primary adult brain tumors[J].Cancer Epidemiol Biomarkers Prev,2007,16(3):559-565.
[20]Koutros S,Berndt SI,Sinha R,et al.Xenobiotic metabolizing gene variants,dietary heterocyclic amine intake,and risk of prostate cancer[J].Cancer Res,2009,69(5):1877-1884.
[21]Jain M,Kumar S,Lal P,et al.Role of gstm3 polymorphism in the risk of developing esophageal cancer[J].Cancer Epidemiol Biomarkers Prev,2007,16(1):178-181.
[22]Sikdar N,Paul RR,Roy B.Glutathione s-transferase m3(a/a) genotype as a risk factor for oral cancer and leukoplakia among indian tobacco smokers[J].Int J Cancer,2004,109(1):95-101.
[23]Holley SL,Rajagopal R,Hoban PR,et al.Polymorphisms in the glutathione s-transferase mu cluster are associated with tumour progression and patient outcome in colorectal cancer[J].Int J Oncol,2006,28(1):231-236.
[24]Kearns PR,Chrzanowska-Lightowlers ZM,Pieters R,et al.Mu class glutathione s-transferase mrna isoform expression in acute lymphoblastic leukaemia[J].Br J Haematol,2003,120(1):80-88.
[25]Peters U,Preisler-Adams S,Hebeisen A,et al.Glutathione s-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin[J].Anticancer Drugs,2000,11(8):639-643.
[26]Inskip A,Elexperu-Camiruaga J,Buxton N,et al.Identification of polymorphism at the glutathione s-transfer,me,gstm3 locus:Evidence for linkage with gstml*a[J-].Biochem J,1995,312(Pt3)(713-716.
[27]Shi Y,Seto E,Chang LS,et al.Transcriptional repression by yyl,a human gli-kruppel-related protein,and relief of repression by adenovirus ela protein[J].Cell,1991,67(2):377-388.
[28]Hariharan N,Kelley DE,Perry RP.Delta,a transcription factor that binds to downstream dements in several polymerase ⅱ promoters,is a functionally versatile zinc finger protein[J].Proe Natl Aead Sci U S A,1991,88(21):9799-9803.
[29]Yengi L,Inskip A,Gilford J,et al.Polymorphism at the glutathione s-transferase locus gstm3:Interactions with cytochrome p450 and glutathione s-transferase genotypes as risk factors for multiple cutaneous basal cell carcinoma[J].Cancer Res,1996,56(9):1974-1977.
[30]Liu X,Campbell MR,Pittman GS,et al.Expression-based discovery of variation in the human glutathione s-transferase m3 promoter and functional analysis in a glioma cell line using allele-specific chromatin immunoprecipitation[J].Cancer Res,2005,65(1):99-104.
[31]Peng D,Razvi MH,Chen H,et al.DNA hypermethylation regulates the expression of members of the mu-class glutathione-s-transferases and glutathione peroxidases in barrett's-related adenocarcinomas[J].Gut,2008:
[32]Board PG,Coggan M,Chelvanayagam G,et al.Identification,characterization,and crystal structure of the omega class glutathione transferases[J].J Biol Chem,2000,275(32):24798-24806.
[33]Dirr H,Reinemer P,Huber R.X-ray crystal structures of cytosolie glutathione s-transferases.Implications for protein architecture,substrate recognition and catalytic function[J].Eur J Bioehem,1994,2200):645-661.
[34]Kim JH,Kim MA,Lee HS,et al.Comparative analysis of protein expressions in primary and metastatic gastric carcinomas[J].Hum Pathol,2009,40(3):314-322.
[35]Shi H,Lu D,Shu Y,et al.Expression of multidrug-resistance-related proteins p-glycoprotein,glutathione-s-transferases,topoisomerase-ⅱ and lung resistance protein in primary gastric cardiac adenocarcinoma[J].Cancer Invest,2008,26(4):344-351.
[36]Delort L,Chalabi N,Satih S,et al.Association between genetic polymorphisms and ovarian cancer risk[J].Antieancer Res,2008,28(5B):3079-3081.
[37]Nagle CM,Chenevix-Trench G,Spurdle AB,et al.The role of glutathione-s-transferase polymorphisms in ovarian cancer survival[J].Eur J Cancer,2007,43(2):283-290.
[38]Muller J,Sidler D,Nachbur U,et al.Thiazolides inhibit growth and induce glutathione-s-transferase pi(gstp 1)-dependent cell death in human colon cancer cells[J].Int J Cancer,2008,123(8):1797-1806.
[39]Gaitanarou E,Seretis E,Xinopoulos D,et al.Immunohistochemical localization of glutathione s-transferase-pi in human colorectal polyps[J].World J Gastroenterol,2008,14(26):4179-4184.
[40]刘军,汪永红,王昌富.谷胱甘肽 s-转移酶-π 的生物学特性及其临床应用[J].INTERNATIONAL JOURNAL,2007,28(1):57-58.
[41]Harbottle A,Daly AK,Atherton K,et al.Role of glutathione s-transferase pl,p-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance[J].Int J Cancer,2001,92(6):777-783.
[42]Masanek U,Stammler G,Volm M.Messenger ma expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin,taxol and cisplatin[J].Anticancer Drugs,1997,8(2):189-198.
[43]Huang G,Mills L,Worth LL.Expression of human glutathione s-transferase pl mediates the chemosensitivity of osteosarcoma cells[J].Mol Cancer Ther,2007,6(5):1610-1619.
[44]Patskovsky YV,Patskovska LN,Listowsky I.An asparagine-phenylalanine substitution accounts for catalytic differences between hgstm3-3 and other human class mu glutathione s-transferases[J].Biochemistry,1999,38(49):16187-16194.
[45]Tetlow N,Robinson A,Mantle T,et al.Polymorphism of human mu class glutathione transferases[J].Pharmacogenetics,2004,14(6):359-368.
[46]Ryoo K,Huh SH,Lee YH,et al.Negative regulation of mekkl-induced signaling by glutathione s-transferase mu[J].J Biol Chem,2004,279(42):43589-43594.
[47]Cho SG,Lee YH,Park HS,et al.Glutathione s-transferase mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1[J].J Biol Chem,2001,276(16):12749-12755.
[48]Lu M,Xia L,Luo D,et al.Dual effects of glutathione-s-transferase pi on as2o3 action in prostate cancer cells:Enhancement of growth inhibition and inhibition of apoptosis[J].Oncogene,2004,23(22):3945-3952.
[49]Yin Z,Ivanov VN,Habelhah H,et al.Glutathione s-transferase p elicits protection against h2o2-induced cell death via coordinated regulation of stress kinases[J].Cancer Res,2000,60(15):4053-4057.
[50]Adler V,Yin Z,Fuchs SY,et al.Regnlation of jnk signaling by gstp[J].EMBO J,1999,18(5):1321-1334.
[2]Paik S,Shak S,Tang G,et al.A multigene assay to predict recurrence of tamoxifen-treated,node-negative breast cancer.N Engl J Med,2004,351(27):2817-2826.
[3]Wang Y,Klijn JG,Zhang Y,et al.Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.Lancet,2005,365(9460):671-679.
[4]van 't Veer LJ,Dai H,van de Vijver MJ,et al.Gene expression profiling predicts clinical outcome of breast cancer.Nature,2002,415(6871):530-536.
[5]Goldhirsch A,Wood WC,Gelber RD,et al.Meeting highlights:Updated international expert consensus on the primary therapy of early breast cancer.J Clin Oncol,2003,21(17):3357-3365.
[6]Marty M,Cognetti F,Maraninchi D,et al.Randomized phase ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:The m77001study group.J Clin Oncol,2005,23(19):4265-4274.
[7]Parl FF.Glutathione s-transferase genotypes and cancer rise Cancer Lett,2005,221(2):123-129.
[8]Mcllwain CC,Townsend DM,Tew KD.Glutathione s-transferase polymorphisms:Cancer incidence and therapy.Oncogene,2006,25(11):1639-1648.
[9]Lee SH,DeJong J.Microsomal gst-i:Genomic organization,expression,and alternative splicing of the human gene.Biochim Biophys Acta,1999,1446(3):389-396.
[10]Inskip A,Elexperu-Camiruaga J,Buxton N,et al.Identification of polymorphism at the glutathione s-transferase,gstm3 locus:Evidence for linkage with gstml*a.Biochem J,1995,312(Pt3)(713-716.
[11]Yengi L,Inskip A,Gilford J,et al.Polymorphism at the glutathione s-transferase locus gstm3:Interactions with cytochrome p450 and glutathione s-transferase genotypes as risk factors for multiple cutaneous basal cell carcinoma.Cancer Res,1996,56(9):1974-1977.
[12]Liu X,Campbell MR,Pittman GS,et al.Expression-based discovery of variation in the human glutathione s-transferase m3 promoter and ftmctional analysis in a glioma cell line using allele-specific chromatin immunoprecipitation.Cancer Res,2005,65(1):99-104.
[13]Mitrunen K,Jourenkova N,Kataja V,et al.Glutathione s-transferase ml,m3,pl,and tl genetic polymorphisms and susceptibility to breast cancer.Cancer Epidemiol Biomarkers Prey, 2001,10(3):229-236.
[14]Koutros S,Bemdt SI,Sinha R,et al.Xenobiotic metabolizing gene variants,dietary heterocyclic amine intake,and risk of prostate cancer.Cancer Res,2009,69(5):1877-1884.
[15]Gemignani F,Landi S,Szeszenia-Dahrowska N,et al.Development of lung cancer before the age of 50:The role of xenobiotic metabolizing genes.Carcinogenesis,2007,28(6):1287-1293.
[16]Jain M,Kumar S,Lal P,et al.Role of gstm3 polymorphism in the risk of developing esophageal cancer.Cancer Epidemiol Biomarkers Prey,2007,16(1):178-181.
[17]Livak KJ,Schmittgen TD.Analysis of relative gene expression data using real-time quantitative per and the 2(-delta delta c(t)) method.Methods,2001,25(4):402-408.
[18]Schleicher E,Wieland OH.Evaluation of the bradford method for protein determination in body fluids.J Clin Chem Clin Biochem,1978,16(9):533-534.
[19]Lo HW,Ali-Osman F.Genetic polymorphism and function of glutathione s-transferases in tumor drug resistance.Curr Opin Pharmacol,2007,7(4):367-374.
[20]Ruwali M,Pant MC,Shah PP,et al.Polymorphism in cytochrome p450 2a6 and glutathione s-transferase pl modifies head and neck cancer risk and treatment outcome.Mutat Res,2009:
[21]Lourenco GJ,Neri IA,Sforni VC,et al.Polymorphisms of glutathione s-trausferase mu 1,glutathione s-transferase theta 1 and glutathione s-transferase pi 1 genes in hodgkin's lymphoma susceptibility and progression.Leuk Lymphoma,2009:1-5.
[22]Piipari R,Nurminen T,Savela K,et al.Glutathione s-transferases and aromatic DNA adducts in smokers' bronchoalveolar macrophages.Lung Cancer,2003,39(3):265-272.
[23]Singh H,Sachan R,Devi S,et al.Association of gstml,gsttl,and gstm3 gene polymorphisms and susceptibility to cervical cancer in a north indian population.Am J Obstet Gynecol,2008,1980):303 e301-306.
[24]Holley SL,Rajagopal R,Hoban PR,et al.Polymorphisms in the glutathione s-trausferase mu cluster are associated with turnout progression and patient outcome in colorectal cancer.Int J Oncol,2006,28(1):231-236.
[25]Dirr H,Reinemer P,Huber R.X-ray crystal structures of cytosolie glutathione s-transferases.Implications for protein architecture,substrate recognition and catalytic function.Eur J Biochem,1994,220(3):645-661.
[26]张飚,李永清,高轩.谷胱甘肽 s-转移酶综述.吉林畜牧兽医,2006,27(006):11-13.
[27]刘军,汪永红,王昌富.谷胱甘肽 s-转移酶-π 的生物学特性及其临床应用.INTERNATIONAL JOURNAL,2007,28(1):57-58.
[28]Wang W,Liu G,Zheng J.Human renal uokl30 tumor cells:A drug resistant cell line with highly selective over-expression of glutathione s-transferase-pi isozyme.Eur J Pharmacol,2007,568(1-3):61-67.
[29]Zhou C,Nitsehke AM,Xiong W,et al.Proteomie analysis of tumor necrosis factor-alpha resistant human breast cancer celia reveals a mek5/erk5-mediated epithelial-mesenchymal transition phenotype.Breast Cancer Res,2008,10(6):R105.
[30]O'Brien M,Kruh GD,Tew KD.The influence of coordinate overexpression of glutathione phase ⅱ detoxification gene products on drug resistance.J Pharmacol Exp Ther,2000,294(2):480-487.
[31]郑肖利,陈建明.阳性脂质体介导基因转染及其研究进展.中国新药杂志,2007,16(023):1930-1935.
[32]Fire A,Xu S,Montgomery MK,et al.Potent and specific genetic interference by double-stranded ma in caenorhabditis elegans.Nature,1998,391(6669):806-811.
[33]Minotti G,Menna P,Salvatorelli E,et al.Anthracyclines:Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.Pharmacol Rev,2004,56(2):185-229.
[34]Huang G,Mills L,Worth LL.Expression of human glutathione s-transferase pl mediates the chemosensitivity of osteosarcoma cells.Mol Cancer Ther,2007,6(5):1610-1619.
[35]Cho SG,Lee YH,Park HS,et al.Glutathione s-transferase mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1.J Biol Chem,2001,276(16):12749-12755.
[36]Adler V,Yin Z,Fuchs SY,et al.Regulation of jnk signaling by gstp.EMBO J,1999,18(5):1321-1334.
[37]Townsend DM,Tew KD.The role of glutathione-s-transferase in anti-cancer drug resistance.Oncogene,2003,22(47):7369-7375.
[38]Lu M,Xia L,Luo D,et al.Dual effects of glutathione-s-transferase pi on as2o3 action in prostate cancer cells:Enhancement of growth inhibition and inhibition of apoptosis.Oncogene,2004,23(22):3945-3952.
[39]Yin Z,Ivanov VN,Habelhah H,et al.Glutathione s-transferase p elicits protection against h2o2-induced cell death via coordinated regulation of stress kinases.Cancer Res,2000,60(15):4053-4057.
[1]Parl FF.Glutathione s-transferase genotypes and cancer risk[J].Cancer Lett,2005,221(2):123-129.
[2]McIlwain CC,Townsend DM,Tew KD.Glutathione s-transferase polymorphisms:Cancer incidence and therapy[J].Oncogene,2006,25(11):1639-1648.
[3]Frova C.Glutathione transferases in the genomics era:New insights and perspectives[J].Biomol Eng,2006,23(4):149-169.
[4]Comstoek KE,Widersten M,Hao XY,et al.A comparison of the enzymatic and physieochemical properties of human glutathione transferase m4-4 and three other human mu class enzymes[J].Arch Biochem Biophys,1994,311(2):487-495.
[5]Campbell E,Takahashi Y,Abramovitz M,et al.A distinct human testis and brain mu-class glutathione s-transferase.Molecular cloning and characterization of a form present even in individuals lacking hepatic type mu isoenzymes[J].J Biol Chem,1990,265(16):9188-9193.
[6]Mitrunen K,Hirvonen A.Molecular epidemiology of sporadic breast cancer.The role of polymorphie genes involved in oestrogen biosynthesis and metabolism[J].Mutat Res,2003,544(1):9-41.
[7]Bieche I,Girault I,Urbain E,et al.Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma[J].Breast Cancer Res,2004,6(3):R252-263.
[8]Mitrunen K,Jourenkova N,Kataja V,et al.Glutathione s-transferase ml,m3,pl,and tl genetic polymorphisms and susceptibility to breast cancer[J].Cancer Epidemiol Biomarkers Prey,2001,10(3):229-236.
[9]Li LF,Xu XJ,Zhao Y,et al.Integrated gene expression profile predicts prognosis of breast cancer patients[J].Breast Cancer Res Treat,2008:
[10]van 't Veer LJ,Dai H,van de Vijver MJ,et al.Gene expression profiling predicts clinical outcome of breast cancer[J].Nature,2002,415(6871):530-536.
[11]Watson MB,Lind MJ,Smith L,et al.Expression microarray analysis reveals genes associated with in vitro resistance to cisplatin in a cell line model[J].Acta Oncol,2007,46(5):651-658.
[12]Monge M,Vilaseca M,Soto-Cerrato V,et al.Proteomic analysis ofprodigiosin-indueed apoptosis in a breast cancer mitoxantrone-resistant(mcf-7 mr) cell line[J].Invest New Drugs,2007,25(1):21-29.
[13]Zienolddiny S,Campa D,Lind H,et al.A comprehensive analysis of phase ⅰ and phase ⅱ metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers[J].Carcinogenesis,2008,29(6):1164-1169.
[14]Piipari R,Nurminen T,Savela K,et al.Glutathione s-transferases and aromatic DNA adducts in smokers' bronchoalveolar macrophages[J].Lung Cancer,2003,390):265-272.
[15]Ye Z,Song H,Higgins JP,et al.Five glutathione s-transferase gene variants in 23,452 cases of lung cancer and 30,397 controls:Meta-analysis of 130 studies[J].PLoS Med,2006,3(4):e91.
[16]Gemignani F,Landi S,Szeszenia-Dabrowska N,et al.Development of lung cancer before the age of 50:The role ofxenobiotie metabolizing genes[J].Carcinogenesis,2007,28(6):1287-1293.
[17]De Roos AJ,Rothman N,Brown M,et al.Variation in genes relevant to aromatic hydrocarbon metabolism and the risk of adult brain tumors[J].Neuro Oncol,2006,8(2):145-155.
[18]Singh H,Sachan R,Devi S,et al.Association of gstml,gsttl,and gstm3 gene polymorphisms and susceptibility to cervical cancer in a north indian population[J].Am J Obstet Gynecol,2008,198(3):303 e301-306.
[19]Schwartzbaum JA,Ahlbom A,Loun S,et al.An international case-control study of glutathione transferase and functionally related polymorphisms and risk of primary adult brain tumors[J].Cancer Epidemiol Biomarkers Prev,2007,16(3):559-565.
[20]Koutros S,Berndt SI,Sinha R,et al.Xenobiotic metabolizing gene variants,dietary heterocyclic amine intake,and risk of prostate cancer[J].Cancer Res,2009,69(5):1877-1884.
[21]Jain M,Kumar S,Lal P,et al.Role of gstm3 polymorphism in the risk of developing esophageal cancer[J].Cancer Epidemiol Biomarkers Prev,2007,16(1):178-181.
[22]Sikdar N,Paul RR,Roy B.Glutathione s-transferase m3(a/a) genotype as a risk factor for oral cancer and leukoplakia among indian tobacco smokers[J].Int J Cancer,2004,109(1):95-101.
[23]Holley SL,Rajagopal R,Hoban PR,et al.Polymorphisms in the glutathione s-transferase mu cluster are associated with tumour progression and patient outcome in colorectal cancer[J].Int J Oncol,2006,28(1):231-236.
[24]Kearns PR,Chrzanowska-Lightowlers ZM,Pieters R,et al.Mu class glutathione s-transferase mrna isoform expression in acute lymphoblastic leukaemia[J].Br J Haematol,2003,120(1):80-88.
[25]Peters U,Preisler-Adams S,Hebeisen A,et al.Glutathione s-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin[J].Anticancer Drugs,2000,11(8):639-643.
[26]Inskip A,Elexperu-Camiruaga J,Buxton N,et al.Identification of polymorphism at the glutathione s-transfer,me,gstm3 locus:Evidence for linkage with gstml*a[J-].Biochem J,1995,312(Pt3)(713-716.
[27]Shi Y,Seto E,Chang LS,et al.Transcriptional repression by yyl,a human gli-kruppel-related protein,and relief of repression by adenovirus ela protein[J].Cell,1991,67(2):377-388.
[28]Hariharan N,Kelley DE,Perry RP.Delta,a transcription factor that binds to downstream dements in several polymerase ⅱ promoters,is a functionally versatile zinc finger protein[J].Proe Natl Aead Sci U S A,1991,88(21):9799-9803.
[29]Yengi L,Inskip A,Gilford J,et al.Polymorphism at the glutathione s-transferase locus gstm3:Interactions with cytochrome p450 and glutathione s-transferase genotypes as risk factors for multiple cutaneous basal cell carcinoma[J].Cancer Res,1996,56(9):1974-1977.
[30]Liu X,Campbell MR,Pittman GS,et al.Expression-based discovery of variation in the human glutathione s-transferase m3 promoter and functional analysis in a glioma cell line using allele-specific chromatin immunoprecipitation[J].Cancer Res,2005,65(1):99-104.
[31]Peng D,Razvi MH,Chen H,et al.DNA hypermethylation regulates the expression of members of the mu-class glutathione-s-transferases and glutathione peroxidases in barrett's-related adenocarcinomas[J].Gut,2008:
[32]Board PG,Coggan M,Chelvanayagam G,et al.Identification,characterization,and crystal structure of the omega class glutathione transferases[J].J Biol Chem,2000,275(32):24798-24806.
[33]Dirr H,Reinemer P,Huber R.X-ray crystal structures of cytosolie glutathione s-transferases.Implications for protein architecture,substrate recognition and catalytic function[J].Eur J Bioehem,1994,2200):645-661.
[34]Kim JH,Kim MA,Lee HS,et al.Comparative analysis of protein expressions in primary and metastatic gastric carcinomas[J].Hum Pathol,2009,40(3):314-322.
[35]Shi H,Lu D,Shu Y,et al.Expression of multidrug-resistance-related proteins p-glycoprotein,glutathione-s-transferases,topoisomerase-ⅱ and lung resistance protein in primary gastric cardiac adenocarcinoma[J].Cancer Invest,2008,26(4):344-351.
[36]Delort L,Chalabi N,Satih S,et al.Association between genetic polymorphisms and ovarian cancer risk[J].Antieancer Res,2008,28(5B):3079-3081.
[37]Nagle CM,Chenevix-Trench G,Spurdle AB,et al.The role of glutathione-s-transferase polymorphisms in ovarian cancer survival[J].Eur J Cancer,2007,43(2):283-290.
[38]Muller J,Sidler D,Nachbur U,et al.Thiazolides inhibit growth and induce glutathione-s-transferase pi(gstp 1)-dependent cell death in human colon cancer cells[J].Int J Cancer,2008,123(8):1797-1806.
[39]Gaitanarou E,Seretis E,Xinopoulos D,et al.Immunohistochemical localization of glutathione s-transferase-pi in human colorectal polyps[J].World J Gastroenterol,2008,14(26):4179-4184.
[40]刘军,汪永红,王昌富.谷胱甘肽 s-转移酶-π 的生物学特性及其临床应用[J].INTERNATIONAL JOURNAL,2007,28(1):57-58.
[41]Harbottle A,Daly AK,Atherton K,et al.Role of glutathione s-transferase pl,p-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance[J].Int J Cancer,2001,92(6):777-783.
[42]Masanek U,Stammler G,Volm M.Messenger ma expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin,taxol and cisplatin[J].Anticancer Drugs,1997,8(2):189-198.
[43]Huang G,Mills L,Worth LL.Expression of human glutathione s-transferase pl mediates the chemosensitivity of osteosarcoma cells[J].Mol Cancer Ther,2007,6(5):1610-1619.
[44]Patskovsky YV,Patskovska LN,Listowsky I.An asparagine-phenylalanine substitution accounts for catalytic differences between hgstm3-3 and other human class mu glutathione s-transferases[J].Biochemistry,1999,38(49):16187-16194.
[45]Tetlow N,Robinson A,Mantle T,et al.Polymorphism of human mu class glutathione transferases[J].Pharmacogenetics,2004,14(6):359-368.
[46]Ryoo K,Huh SH,Lee YH,et al.Negative regulation of mekkl-induced signaling by glutathione s-transferase mu[J].J Biol Chem,2004,279(42):43589-43594.
[47]Cho SG,Lee YH,Park HS,et al.Glutathione s-transferase mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1[J].J Biol Chem,2001,276(16):12749-12755.
[48]Lu M,Xia L,Luo D,et al.Dual effects of glutathione-s-transferase pi on as2o3 action in prostate cancer cells:Enhancement of growth inhibition and inhibition of apoptosis[J].Oncogene,2004,23(22):3945-3952.
[49]Yin Z,Ivanov VN,Habelhah H,et al.Glutathione s-transferase p elicits protection against h2o2-induced cell death via coordinated regulation of stress kinases[J].Cancer Res,2000,60(15):4053-4057.
[50]Adler V,Yin Z,Fuchs SY,et al.Regnlation of jnk signaling by gstp[J].EMBO J,1999,18(5):1321-1334.